About the Clinical Trial The clinical trial, entitled “Safety and Efficacy of iPSC-derived Mesenchymal Stromal Cell
Therapy in Renal Transplant Recipients – the Nereid Study”, is an open label, non-randomized, non-blinded, prospective, single centre clinical phase Ib study. It will be conducted in 10 renal allograft recipients, aged 18-75 years old.
The principal investigator is Dr. HS Spijker, Department of Nephrology, LUMC.
Following their transplant surgery, patients will receive a drug used to treat graft rejection and two doses of Cymerus MSCs 6 and 7 weeks after transplantation followed by withdrawal of anti-rejection medication.
The primary end point is safety by assessing absence of acute rejection (absence of graft loss after 6 months) after withdrawal of anti-rejection medication. Other end points include assessment of renal function at 6 months and the incidence of opportunistic infections
CYP Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)